Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2008

01-04-2008 | Original Paper

Influence of Insulin Resistance and Adipokines in the Grade of Steatosis of Nonalcoholic Fatty Liver Disease

Authors: Rocio Aller, Daniel A. de Luis, Luis Fernandez, Fernando Calle, Benito Velayos, Jose Luis Olcoz, Olatz Izaola, Manuel Gonzalez Sagrado, Rosa Conde, Jose Manuel Gonzalez

Published in: Digestive Diseases and Sciences | Issue 4/2008

Login to get access

Abstract

The objective of this work was to study the influence of insulin resistance and adipokines on the grade of steatosis in patients with NAFLD (nonalcoholic fatty liver disease) diagnosed by liver biopsy. A sample of 24 NAFLD patients was analyzed in a cross-sectional study. All patients with a two-week weight-stabilization period before recruitment were enrolled. A liver biopsy was realized. Weight, basal glucose, insulin, insulin resistance (HOMA), total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and adipokines blood levels were measured. A nutritional evaluation (dietary intake, indirect calorimetry, and bioimpedance) was performed. The mean age was 41.6 ± 8.7 years and the mean body mass index (BMI) 29.4 ± 4.7. Twelve patients had a low grade of steatosis (grade 1 of the Brunt classification) and 12 patients had a high grade of steatosis (grade 2 or 3). Only HOMA was higher in patients with a high grade of steatosis (1.4 ± 0.5 vs. 2.8 ± 1.7 units; P < 0.05). Anthropometric data and dietary intake were similar for both groups. Blood levels of adiponectin were higher in patients with a low grade of steatosis (37.7 ± 22.5 vs. 24.2 ± 33 ng mL−1; P < 0.05). Blood levels of resistin were higher in patients with a high grade of steatosis (2.36 ± 0.6 vs. 2.8 ± 0.6 mg mL−1; P < 0.05), without differences in TNF-α or leptin levels. In logistic regression analysis, the HOMA-IR remained in the model, with an odds ratio to develop high grade of steatosis of 7.8 (95% CI: 1.8–75) with each 1 unit of HOMA-IR adjusted by age, sex, BMI, and dietary intake. This study demonstrates that insulin resistance determined with the HOMA model is associated with a high grade of steatosis in patients with NAFLD.
Literature
1.
go back to reference Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proc 55:434–438 Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proc 55:434–438
2.
go back to reference Chitturi S, Abeygunasekera S, Farell GC, Holmes-Walker J, Hui M, Fung C, Karim R (2002) NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373–379PubMedCrossRef Chitturi S, Abeygunasekera S, Farell GC, Holmes-Walker J, Hui M, Fung C, Karim R (2002) NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373–379PubMedCrossRef
3.
go back to reference Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG (1999) Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84:1513–1517PubMedCrossRef Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG (1999) Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84:1513–1517PubMedCrossRef
4.
go back to reference Kumada M, Kihara S, Sumitsuji S (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89PubMedCrossRef Kumada M, Kihara S, Sumitsuji S (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85–89PubMedCrossRef
5.
go back to reference Shimomoura I, Hammer RE, Ikemoto S (1999) Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73–76CrossRef Shimomoura I, Hammer RE, Ikemoto S (1999) Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73–76CrossRef
6.
go back to reference Steppan CM, Bailey ST, Bhat S (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312PubMedCrossRef Steppan CM, Bailey ST, Bhat S (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312PubMedCrossRef
7.
8.
go back to reference Matthews DR, Hosker JP, Rudenski AS (1985) Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef Matthews DR, Hosker JP, Rudenski AS (1985) Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRef
9.
go back to reference Piccoli A (1995) Identification of operational clues to dry weight prescription in hemodialysis using bioimpedance vector analysis. Kidney Int 53:1036CrossRef Piccoli A (1995) Identification of operational clues to dry weight prescription in hemodialysis using bioimpedance vector analysis. Kidney Int 53:1036CrossRef
10.
go back to reference Mataix J, Mañas M (1998) Tablas de composición de alimentos españoles. Ed: University of Granada Mataix J, Mañas M (1998) Tablas de composición de alimentos españoles. Ed: University of Granada
11.
go back to reference Feurer ID, Mullen JL (1986) Bedside measurement of resting energy expenditure and respiratory quotient via indirect calorimetry. Nutr Clin Pract 1:43–49 Feurer ID, Mullen JL (1986) Bedside measurement of resting energy expenditure and respiratory quotient via indirect calorimetry. Nutr Clin Pract 1:43–49
12.
13.
go back to reference Marchesini G, Brizi M, Morselli-Labate A, Bianchi G, Bugianesi E, McCullough AJ (1999) Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107:450–454PubMedCrossRef Marchesini G, Brizi M, Morselli-Labate A, Bianchi G, Bugianesi E, McCullough AJ (1999) Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107:450–454PubMedCrossRef
14.
go back to reference Sanyal AJ, Campbell Sargent C, Mirshashi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitocohondrial abnormalities. Gastroenterology 120:1183–1192PubMedCrossRef Sanyal AJ, Campbell Sargent C, Mirshashi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitocohondrial abnormalities. Gastroenterology 120:1183–1192PubMedCrossRef
15.
go back to reference Rashid M, Roberts EA (2000) Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 30:48–53PubMedCrossRef Rashid M, Roberts EA (2000) Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 30:48–53PubMedCrossRef
16.
go back to reference Chitturi S, Abeygunasekera S, Farrell G, Holmes-Walker J (2002) NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 73:373–378CrossRef Chitturi S, Abeygunasekera S, Farrell G, Holmes-Walker J (2002) NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 73:373–378CrossRef
17.
go back to reference Venturi C, Zoppini G, Zamboni C, Muggeo M (2004) Insulin sensitivity, hepatic steatosis in obese subjects with normal glucose tolerance. Nutr Metab Cardiovasc Dis 14:200–204PubMedCrossRef Venturi C, Zoppini G, Zamboni C, Muggeo M (2004) Insulin sensitivity, hepatic steatosis in obese subjects with normal glucose tolerance. Nutr Metab Cardiovasc Dis 14:200–204PubMedCrossRef
18.
go back to reference Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis, liver injury. J Clin Invest 114:147–152PubMed Browning JD, Horton JD (2004) Molecular mediators of hepatic steatosis, liver injury. J Clin Invest 114:147–152PubMed
19.
go back to reference Pagano C, Soardoo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G (2005) Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152:113–118PubMedCrossRef Pagano C, Soardoo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G (2005) Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 152:113–118PubMedCrossRef
20.
go back to reference Shklyaev S, Aslanidi G, Tennant M, Prima V, Kohlbrenner E, Kroutov V (2003) Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA 100:14217–14222PubMedCrossRef Shklyaev S, Aslanidi G, Tennant M, Prima V, Kohlbrenner E, Kroutov V (2003) Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA 100:14217–14222PubMedCrossRef
21.
go back to reference Fernandez Real JM, Vendrell J, Ricart W (2005) Circulating adiponectin and plasma fatty acid profile. Clin Chem 51:603–609PubMedCrossRef Fernandez Real JM, Vendrell J, Ricart W (2005) Circulating adiponectin and plasma fatty acid profile. Clin Chem 51:603–609PubMedCrossRef
22.
go back to reference Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J (2004) Beyond insulin resistance in NASH: TNF alpha or adiponectin? Hepatology 40:46–54PubMedCrossRef Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J (2004) Beyond insulin resistance in NASH: TNF alpha or adiponectin? Hepatology 40:46–54PubMedCrossRef
23.
go back to reference Yagmur E, Trautwein C, Gressner AM, Tacke E (2006) Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver disease. Am J Gastroenterol 101:1244–1252PubMedCrossRef Yagmur E, Trautwein C, Gressner AM, Tacke E (2006) Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver disease. Am J Gastroenterol 101:1244–1252PubMedCrossRef
24.
go back to reference Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G et al (2006) Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 91:101–1086CrossRef Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G et al (2006) Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 91:101–1086CrossRef
Metadata
Title
Influence of Insulin Resistance and Adipokines in the Grade of Steatosis of Nonalcoholic Fatty Liver Disease
Authors
Rocio Aller
Daniel A. de Luis
Luis Fernandez
Fernando Calle
Benito Velayos
Jose Luis Olcoz
Olatz Izaola
Manuel Gonzalez Sagrado
Rosa Conde
Jose Manuel Gonzalez
Publication date
01-04-2008
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2008
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9981-3

Other articles of this Issue 4/2008

Digestive Diseases and Sciences 4/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.